Thrombotic thrombocytopenic purpura

Source: Wikipedia, the free encyclopedia.
Not to be confused with Immune thrombocytopenic purpura.
Thrombotic thrombocytopenic purpura
Other namesMoschcowitz syndrome,
immunosuppressants[1]
Prognosis< 20% risk of death[1]
Frequency1 in 100,000 people[3]

Thrombotic thrombocytopenic purpura (TTP) is a

large bruises, fever, weakness, shortness of breath, confusion, and headache.[2][3] Repeated episodes may occur.[3]

In about half of cases a trigger is identified, while in the remainder the cause remains unknown.

multimers of von Willebrand factor (vWF) into smaller units.[1] Less commonly TTP is inherited, known as Upshaw–Schulman syndrome, such that ADAMTS13 dysfunction is present from birth.[5] Diagnosis is typically based on symptoms and blood tests.[2] It may be supported by measuring activity of or antibodies against ADAMTS13.[2]

With

glucocorticoids, and rituximab may also be used.[3] Platelet transfusions are generally not recommended.[6]

About 1 per 100,000 people are affected.[3] Onset is typically in adulthood and women are more often affected.[3] About 10% of cases begin in childhood.[3] The condition was first described by Eli Moschcowitz in 1924.[3] The underlying mechanism was determined in the 1980s and 1990s.[3]

Signs and symptoms

The signs and symptoms of TTP may at first be subtle and nonspecific. Many people experience an

High blood pressure has also been observed as a symptom.[10]

As TTP progresses, blood clots form within small blood vessels (microvasculature), and platelets (clotting cells) are consumed. As a result, bruising, and rarely bleeding can occur. The bruising often takes the form of purpura, while the most common site of bleeding, if it occurs, is from the nose or gums. Larger bruises (

ecchymoses) may also develop.[11] The classic presentation of TTP, which occurs in less than 10% of people, includes five medical signs. These are:[3]

Causes

TTP, as with other

congenital TTP: an inherited deficiency of ADAMTS13 (known as the Upshaw–Schulman syndrome).[12]

Autoimmune

In 1998, the majority of cases were shown to be caused by the inhibition of the enzyme

New England Journal of Medicine.[14]

ADAMTS13 is a

blood clots, and the blood vessel wall in the process of blood coagulation. Very large vWF multimers are more prone to lead to coagulation. Hence, without proper cleavage of vWF by ADAMTS13, coagulation occurs at a higher rate, especially in the microvasculature, part of the blood vessel system where vWF is most active due to high shear stress.[5]

Genetic

Thrombotic thrombocytopenic purpura is inherited in an autosomal recessive manner.[15][16]

TTP may also be

congenital. Such cases may be caused by mutations in the ADAMTS13 gene.[17][18] This hereditary form of TTP is called the Upshaw–Schulman syndrome (also spelled Upshaw–Schülman).[19][20] People with this inherited ADAMTS13 deficiency have a surprisingly mild phenotype, but develop TTP in clinical situations with increased von Willebrand factor levels, e.g. infection. Reportedly, less than 5% of all TTP cases are due to Upshaw–Schulman syndrome.[21] People with this syndrome generally have 5–10% of normal ADAMTS-13 activity.[22][23]

Secondary

Secondary TTP is diagnosed when the person's history mentions one of the known features associated with TTP. It comprises about 40% of all cases of TTP. Predisposing factors are:[12]

The mechanism of secondary TTP is poorly understood, as ADAMTS13 activity is generally not as depressed as in idiopathic TTP, and inhibitors cannot be detected. Probable etiology may involve, at least in some cases, endothelial damage,[25] although the formation of thrombi resulting in vessel occlusion may not be essential in the pathogenesis of secondary TTP.[26] These factors may also be considered a form of secondary aHUS; people presenting with these features are, therefore, potential candidates for anticomplement therapy.

Pathophysiology

The underlying mechanism typically involves autoantibody-mediated inhibition of the enzyme

metalloprotease responsible for cleaving large multimers of von Willebrand factor (vWF) into smaller units. The increase in circulating multimers of vWF increases platelet adhesion to areas of endothelial injury, particularly where arterioles and capillaries meet, which in turn results in the formation of small platelet clots called thrombi.[27] As platelets are used up in the formation of thrombi, this then leads to a decrease in the number of overall circulating platelets, which may then cause life-threatening bleeds. Red blood cells passing the microscopic clots are subjected to shear stress, which damages their membranes, leading to rupture of red blood cells within blood vessels,[9] which in turn leads to microangiopathic hemolytic anemia and schistocyte formation. The presence of the thrombi reduces blood flow to organs resulting in cellular injury and end organ damage.[13]

Recovery

Depression is common in those recovering from TTP; 59% of recovered TTP patients screened positive for depression within 11 years after recovery.[28]

Diagnosis

Differential diagnosis

TTP is a form of

neurological symptoms. Generally, TTP has higher rates of neurological symptoms (≤80%) and lower rates of renal symptoms (9%) than HUS (10–20% and 90%, respectively).[30]

Unlike HUS and aHUS,

enterohemorrhagic E. coli (EHEC), are more likely indicative of HUS,[34] whereas absence of shiga-toxin/EHEC can confirm a diagnosis of aHUS.[27]

Treatment

Due to the high mortality of untreated TTP, a

presumptive diagnosis of TTP is made even when only microangiopathic hemolytic anemia and thrombocytopenia are seen, and therapy is started. Transfusion is contraindicated in thrombotic TTP, as it fuels the coagulopathy. Since the early 1990s, plasmapheresis has become the treatment of choice for TTP.[35][36] This is an exchange transfusion involving removal of the person's blood plasma through apheresis and replacement with donor plasma (fresh frozen plasma or cryosupernatant); the procedure must be repeated daily to eliminate the inhibitor and abate the symptoms. If apheresis is not available, fresh frozen plasma can be infused, but the volume that can be given safely is limited due to the danger of fluid overload.[37] Plasma infusion alone is not as beneficial as plasma exchange.[35] Corticosteroids (prednisone or prednisolone) are usually given.[36] Rituximab, a monoclonal antibody aimed at the CD20 molecule on B lymphocytes, may be used on diagnosis; this is thought to kill the B cells and thereby reduce the production of the inhibitor.[36] A stronger recommendation for rituximab exists where TTP does not respond to corticosteroids and plasmapheresis.[36]

Caplacizumab is an alternative option in treating TTP as it has been shown that it induces a faster disease resolution compared with those people who were on placebo.[38] However, the use of caplacizumab was associated with increase bleeding tendencies in some studied subjects.[39]

People with refractory or relapsing TTP may receive additional

cyclosporine A, or splenectomy.[3][37]

Children with Upshaw-Schulman syndrome receive prophylactic plasma every two to three weeks; this maintains adequate levels of functioning ADAMTS13. Some tolerate longer intervals between plasma infusions. Additional plasma infusions may be necessary for triggering events, such as surgery; alternatively, the platelet count may be monitored closely around these events with plasma being administered if the count drops.[40]

Measurements of blood levels of lactate dehydrogenase, platelets, and schistocytes are used to monitor disease progression or remission.[13][41] ADAMTS13 activity and inhibitor levels may be measured during follow-up, but in those without symptoms the use of rituximab is not recommended.[36]

Apadamtase alfa (Adzynma) was approved for medical use in the United States in November 2023.[42][43]

Prognosis

The mortality rate is around 95% for untreated cases, but the prognosis is reasonably favorable (80–90% survival) for people with idiopathic TTP diagnosed and treated early with plasmapheresis.[44]

Epidemiology

The incidence of TTP is about 4–5 cases per million people per year.

systemic lupus erythematosus occurs more frequently in people of African descent, although other secondary forms do not show this distribution.[46] Although Black people are at an increased risk for TTP, its presentation in Black people does not have any distinguishable features compared to those of other races.[47] Pregnant women and women in the post partum period accounted for a notable portion (12–31%) of the cases in some studies; TTP affects about one in 25,000 pregnancies.[48]

History

TTP was initially described by

small and large bruises, microscopic hematuria, and, at autopsy, disseminated microvascular thrombi.[50] In 1966, a review of 16 new cases and 255 previously reported cases led to the formulation of the classical pentad of symptoms and findings (i.e., thrombocytopenia, microangiopathic hemolytic anemia, neurological symptoms, kidney failure, fever); in this series, mortality rates were found to be very high (90%).[51]

While a response to blood transfusion had been noted before, a 1978 report and subsequent studies showed blood plasma was highly effective in improving the disease process.[52] In 1991, plasma exchange was reported to provide better response rates compared to plasma infusion.[53] In 1982, the disease had been linked with abnormally large von Willebrand factor multimers. The identification of a deficient protease in people with TTP was made in 1998. The location of ADAMTS13 within the human genome was identified in 2001.[52]

References

  1. ^
    S2CID 11960153
    .
  2. ^
    Genetic and Rare Diseases Information Center. U.S. Department of Health & Human Services. Archived from the original
    on 2018-10-20. Retrieved 2018-10-10.
  3. ^
    S2CID 2543348
    .
  4. ^
    S2CID 26844964
    .
  5. ^
    PMID 14727254
    .
  6. ISBN 978-1-56053-516-4
    .
  7. ^
    S2CID 24123004
    .
  8. National Library of Medicine
    .
  9. ^ a b "Platelet Disorders - Thrombotic Thrombocytopenic Purpura (TTP)". National Heart, Lung, and Blood Institute. 24 March 2022 [Updated March 24, 2022].
  10. S2CID 139098502
    .
  11. S2CID 54564230
    .
  12. ^
    S2CID 40055198
    .
  13. ^
    PMID 28613472
    .
  14. PMID 9828253
    .
  15. OMIM
    .
  16. ^ "Thrombotic thrombocytopenic purpura". Orphanet.
  17. S2CID 3470460
    .
  18. S2CID 17777111
    .
  19. S2CID 204864996
    .
  20. S2CID 13963783
    .
  21. ISBN 978-1-975184-69-8
    .
  22. S2CID 4380010
    .
  23. S2CID 20496927
    .
  24. ISBN 9780781751049
    .
  25. PMID 10381511
    .
  26. PMID 11418383
    .
  27. ^
    PMID 20058209
    .
  28. PMID 25975932
    .
  29. ^
    PMID 27754896
    .
  30. ^ "MAHA, TTP, HUS, DIC... Oh My! Understanding Microangiopathic Hemolytic Anemias". Tampa Emergency Medicine Blog. University of South Florida. 2023-04-26. Retrieved 2023-08-23.
  31. ISBN 978-1437716047
    . In contrast to TTP, HUS is not caused by a deficiency of ADAMTS13.
  32. PMID 23847193
    . Complement dysregulation leads to atypical hemolytic uremic syndrome (aHUS), while ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura.
  33. PMID 24599547
    .
  34. S2CID 6129618
    .
  35. ^
    PMID 19160220
    .
  36. ^
    PMID 25573992
    .
  37. ^
    S2CID 38774829
    .
  38. S2CID 19482364
    .
  39. PMID 36485149
    .
  40. S2CID 22209831
    .
  41. ^
    S2CID 40493167
    .
  42. ^ "FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder". U.S. Food and Drug Administration (Press release). 9 November 2023. Retrieved 30 November 2023.
  43. ^ "Takeda's Adzynma (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)" (Press release). Takeda Pharmaceuticals. 9 November 2023. Retrieved 30 November 2023 – via Business Wire.
  44. PMID 16409158
    .
  45. S2CID 24914279
    .
  46. S2CID 23118040
    .
  47. PMID 27383202
    .
  48. PMID 18215115
    .
  49. PMID 33540569
    .
  50. ^ Moschcowitz E (1924). "Hyaline Thrombosis of the Terminal Arterioles and Capillaries: A Hitherto Undescribed Disease". Proceedings of the New York Pathological Society. 24: 21–24.
  51. S2CID 71943329
    .
  52. ^
    PMID 18574040
    .
  53. PMID 2062330
    .

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Thrombotic_thrombocytopenic_purpura&oldid=1210934518"